Grace Science CEO Matt Wilsey says FDA demands could kill its gene therapy for the rare and fatal NGLY1 deficiency by September without new funding or a regulatory break.
June 9, 2026 02:22 PM EDT
A father built a gene therapy for his daughter. He says an FDA request is the bottleneck
Grace Science appeared to be one of the few companies fighting ultra-rare diseases whose gene therapy candidate might make it across the finish line.
Co-founded …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
A UCSF team has submitted an application to the FDA seeking approval for a small trial of in utero gene therapy for a rare…
Doctors have linked a boy's tumor to a gene therapy, but say the rare risks need to be weighed against the profound benefits such…
On Thursday, the American Society of Gene & Cell Therapy (ASGCT) and the Orphan Therapeutics Accelerator (OTXL) debuted a joint…
“We’re still very much in the early stages,” a gene therapy expert said. “But every day, he’s showing us signs that he’s growing…
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA…
